<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01523184</url>
  </required_header>
  <id_info>
    <org_study_id>YKP10811C003</org_study_id>
    <nct_id>NCT01523184</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation</brief_title>
  <official_title>A Phase II, Single-Center, Randomized, Parallel Group, Multiple Administration, Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Life Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Life Science</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a single-center, randomized, parallel group, multiple dose administration,
      double-blind, placebo-controlled study to evaluate the effects of YKP10811 on gastric, small
      bowel, and colonic transit in patients with Chronic Constipation or Functional Constipation.
      Four groups including a placebo group will be enrolled and will receive multiple oral doses
      of YKP10811 or matching placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If the participant fulfills the initial eligibility criteria, the patient will be randomized
      to 1 of the active treatment groups or placebo. During the treatment period, patients will
      receive study medication once daily for 8 days. Patients will undergo scintigraphic
      assessment of gastric, small bowel and colonic transit of solids over the 48-hour period.

      Patients will be males or females, 18 through 65 years of age with a body mass index (BMI) of
      19 through 40 kg/m2, with Chronic Constipation or Functional Constipation and no evidence of
      evacuation disorder as assessed by the Investigator and meet all the inclusion criteria and
      none of the exclusion criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colonic Geometric Center (GC) at 24 hours</measure>
    <time_frame>48 hours</time_frame>
    <description>The colonic GC at 24 hours is the measurement of the move of the food within the GI track.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying half time</measure>
    <time_frame>4 hours</time_frame>
    <description>The gastric emptying half time is the time to empty the half of the ingested solid food in the stomach.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Chronic Constipation</condition>
  <condition>Functional Constipation</condition>
  <arm_group>
    <arm_group_label>Placebo Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YKP10811 Drug Product Capsule, 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>YKP10811 Drug Product Capsule, 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>YKP10811 Drug Product Capsule, 30 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Capsule</intervention_name>
    <description>This is the placebo capsule</description>
    <arm_group_label>Placebo Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YKP10811 Drug Product Capsule</intervention_name>
    <description>The drug product, YKP10811, 10 mg under investigation</description>
    <arm_group_label>YKP10811 Drug Product Capsule, 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YKP10811 Drug Product Capsule</intervention_name>
    <description>The drug product, YKP10811, 20 mg under investigation</description>
    <arm_group_label>YKP10811 Drug Product Capsule, 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YKP10811 Drug Product Capsule</intervention_name>
    <description>The drug product, YKP10811, 30 mg under investigation</description>
    <arm_group_label>YKP10811 Drug Product Capsule, 30 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Non-smokers (refrained from any tobacco or nicotine usage, including smokeless
             tobacco, nicotine patches, etc.) for at least 6 months prior to Day 1 of the study

          2. Body Mass Index of 19 through 40 kg/m2

          3. Participants must be willing to follow dietary restrictions

          4. Females of childbearing potential (ie, not menopausal, no hysterectomy, no bilateral
             oophorectomy) must complete a negative pregnancy test (urine) prior to receiving any
             radioisotopes

          5. No evidence of pelvic floor dysfunction

          6. If clinically indicated, absence of an evacuation disorder should be confirmed within
             30 days prior to the first dose of study medication

          7. At Screening, patients must meet ROME III Criteria for FC, which assumes an absence of
             a structural or biochemical explanation

          8. The patient's screening (baseline) colonic transit test must show a GC ≤ 2.4 at 24
             hours; and

          9. Baseline EKG shows QTc interval ≤ 450mSec

        Exclusion Criteria:

          1. History of clinically-significant manifestations or current abnormality of any organ
             system

          2. History of inflammatory bowel disease

          3. Any history of GI surgery within 6 months prior to the first dose of study medication

          4. History of clinically-significant prolonged diarrhea, in the absence of a laxative

          5. Patients who have started a special dietary habit and/or an intense physical workout
             program within 4 weeks prior to the first dose of study medication

          6. Any clinically-significant surgical procedure within 30 days prior to the first dose
             of study medication

          7. History of alcoholism or drug addiction within 12 months prior to the first dose of
             study medication

          8. Any patient who has had an acute illness within 5 days prior to the first dose of
             study medication, eg, flu syndrome, GI virus, indigestion

          9. Patients who are breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Camilleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2012</study_first_submitted>
  <study_first_submitted_qc>January 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <disposition_first_submitted>July 1, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>July 1, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 3, 2014</disposition_first_posted>
  <last_update_submitted>July 2, 2014</last_update_submitted>
  <last_update_submitted_qc>July 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic constipation (CC)</keyword>
  <keyword>Functional Constipation (FC)</keyword>
  <keyword>Gastric Emptying</keyword>
  <keyword>Colon Transit</keyword>
  <keyword>multiple doses of YKP10811</keyword>
  <keyword>gastrointestinal transit</keyword>
  <keyword>colonic transit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

